What is Circle Pharma?
Circle Pharma operates an indication-agnostic discovery engine dedicated to the development of cell-permeable macro-cyclic peptide therapeutics. Leveraging a computational structure-based design approach, the company targets complex therapeutic areas that are difficult to address with conventional small molecules. Founded in 2012 and headquartered in San Francisco, California, Circle Pharma is positioned at the forefront of peptide-based drug discovery, aiming to unlock new treatment modalities for a range of diseases.
How much funding has Circle Pharma raised?
Circle Pharma has raised a total of $204.8M across 4 funding rounds:
Series A
$3.8M
Series B
$45M
Series C
$66M
Series D
$90M
Series A (2016): $3.8M with participation from ShangPharma Investment Group, Ltd, Mission Bay Capital, and Pfizer Inc
Series B (2020): $45M led by Nextech Invest Ltd, ShangPharma Innovation Inc, Lifeforce Capital, Berkeley Catalyst Fund, and The Column Group
Series C (2021): $66M supported by Euclidean Capital, Hartford HealthCare Endowment, Eli Lilly and Company, Pavillion Capital, Nextech Invest, The Column Group, and Pandect Bioventures
Series D (2024): $90M featuring Euclidean Capital, Nextech Invest, and The Column Group
Key Investors in Circle Pharma
Euclidean Capital
Euclid Capital is a company in the process of launching its services, focusing on providing updates to interested parties through a subscription model. They emphasize user experience and are focused on traffic analysis.
Nextech Invest
Nextech Invest is a Zurich-based company dedicated to accelerating advancements in precision medicine by identifying transformative cancer medicines. They focus on nurturing emerging biotechnology companies worldwide.
The Column Group
The Column Group (TCG) is a venture ecosystem focused on advancing scientific innovation in the life sciences sector. With a history of funding key advancements in biotechnology, TCG has supported the formation and growth of 55 companies.
What's next for Circle Pharma?
The substantial enterprise-level funding, culminating in the recent Series D round, positions Circle Pharma for accelerated development and potential commercialization of its therapeutic pipeline. This significant capital infusion is expected to fuel further research and development, expand its discovery engine capabilities, and potentially advance its lead candidates through clinical trials. The strategic backing from prominent life science investors suggests a clear path toward addressing unmet medical needs and solidifying its market position in the competitive biopharmaceutical landscape.
See full Circle Pharma company page
